Abrax Japan English https://validator.w3.org/feed/docs/rss2.html Abrax Japan in EN Abrax Japan Renews Joint Research Agreement with Kyushu University Abrax Japan’s lead asset ABX was featured in an information program on the TBS network Abrax Japan and Kyushu University Graduate School concluded Joint Research Agreement Sample post6 Sample post5 Sample post4 Sample post3 Sample service3 Sample post2 Sample service2 Sample service1 Sample post1 Sample Page Hello world! Abrax Japan Appoints Dr. William Chin and Dr. Zoltan Arany to its Scientific Advisory Board Partners Benefits of Sebum Secretion Management Team Company Abrax Japan’s Revolutionary Obesity Treatment F-275 Featured on Nippon Television with Dr. Kambayashi Leveraging the skin to heal the body Abrax Science Formulytica Abrax Japan establishes a subsidiary company, Abrax Australia PTY LTD, in Australia. Co-founder of Abrax Japan, Dr. Taku Kambayashi, publishes article in Science entitled “Thymic stromal lymphopoietin induces adipose loss through sebum hypersecretion” Abrax Japan announces $3 million Seed 4 financing to support clinical development of ABX-919 for atopic dermatitis Dr. Kambayashi wins both competitions in STAT Madness 2022 Abrax Japan Announces License Agreement with the University of Pennsylvania Abrax Japan Announces Completion of IND-Enabling Safety Studies to Advance Lead Program towards Clinical Trials Dr. Taku Kambayashi will appear on Nippon TV series “Learn with Kazu-Laser” on June 20, 2023. FAQ / Contact Blog Abrax Japan Announces Innovative Approach to Stimulate Weight Loss and Seek FDA Approval for Lipid Disorders Pipeline